We scan new podcasts and send you the top 5 insights daily.
Historic VEGF inhibitors in lung cancer improved progression-free survival without yielding overall survival gains. The phase 3 HARMONY-6 trial broke this pattern by showing a statistically and clinically significant median overall survival improvement of 27 versus 23 months (hazard ratio 0.66) when combining ivonescimab with chemotherapy.
Frontline VEGF inhibition was historically avoided in squamous non-small cell lung cancer due to severe bleeding risks. In the HARMONY-6 study, excluding patients with large cavitary lesions or significant hemoptysis kept severe grade 3 or higher hemorrhage and arterial thromboembolism uncommon.
The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.
The HARMONY-2 study showed Ivanesimab delivered a median progression-free survival of 11.3 months compared to 5.8 months for Pembrolizumab in PD-L1 positive NSCLC. Analysis confirmed Pembrolizumab performed as expected, suggesting the dual VEGF/PD-1 blockade provides a genuinely superior clinical benefit over PD-1 inhibition alone.
Patients with EGFR-mutated lung cancer progressing on frontline TKIs frequently exhibit CNS metastases and historically respond poorly to checkpoint inhibitors. In the HARMONY trial, adding ivonescimab to chemotherapy preserved progression-free survival benefits and actually produced greater additive benefit in patients presenting with brain metastases.
Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.
In the HARMONY A study, Ivanesimab plus chemotherapy significantly improved progression-free survival in EGFR-mutant non-small cell lung cancer patients. This is notable because prior trials showed that adding standard PD-1 inhibitors to chemotherapy was ineffective for this specific patient population.
Simultaneous targeting of VEGF and checkpoint inhibition raised concerns regarding compounded toxicities, but clinicians view the side-effect profile as familiar. Polling and trial results suggest ivonescimab's VEGF-related toxicities remain mostly low grade and are comparable to or more manageable than historical monoclonal antibodies like bevacizumab.
Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.
Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.
The next wave in NSCLC immunotherapy involves bispecific antibodies, which are single molecules that simultaneously block both the PD-1/PD-L1 and VEGF pathways. Agents like Ivanesimab are showing superior progression-free survival compared to standard checkpoint inhibitors, establishing this dual-target approach as a leading area of development.